Pyrazinamide--on the antituberculosis drug frontline.
Mitchison
D A
DA
Department of Medical Microbiology, St George's Hospital Medical School, London, UK.
D000581:Amidohydrolases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000995:Antitubercular Agents / Q000494:pharmacology / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004352:Drug Resistance, Microbial / Q000235:genetics*; D006801:Humans; D051379:Mice; D011718:Pyrazinamide / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use*; D014376:Tuberculosis / Q000188:drug therapy* / Q000382:microbiology
D000995:Antitubercular Agents; D011718:Pyrazinamide; C005296:pyrazinoic acid; D000581:Amidohydrolases; C019665:amidase